REVIEW article
Front. Cell. Neurosci.
Sec. Non-Neuronal Cells
Volume 19 - 2025 | doi: 10.3389/fncel.2025.1645437
Vascular Endothelial Growth Factor: A Key Factor in the Onset and Treatment of Depression
Provisionally accepted
- 1The Graduate School, Heilongjiang University of Chinese Medicine, Harbin, China
- 2Department of Rheumatology and Immunology, First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, China
- 3First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Major depressive disorder (MDD) is a common chronic psychiatric disorder that affects individuals of all ages worldwide, causing significant impairment to patients' physical and mental health as well as social functioning. Vascular endothelial growth factor (VEGF), traditionally recognized as a regulator of angiogenesis and vascular permeability, has been identified in recent studies to possess neurotrophic and neuroprotective potential in the central nervous system (CNS) and is implicated in the pathological processes of MDD. Aim: To systematically elaborate on the role of VEGF in the pathological mechanisms of MDD and its potential as a target for antidepressant therapy. Key Findings: Through interactions with its receptors (VEGFR1, VEGFR2, and VEGFR3), VEGF regulates critical pathways such as gene expression, blood-brain barrier (BBB) function, and brain-derived neurotrophic factor (BDNF), thereby establishing physiological and pathological associations with MDD. Its signaling pathway serves as a core target for various antidepressant treatments, including conventional antidepressants, ketamine, electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), and resolvins. Short-term upregulation of central VEGF may exert antidepressant effects by promoting the benign remodeling of neurovascular networks, and its subsequent return to baseline levels during treatment can avoid BBB damage, providing novel insights for the management of rapid-onset and treatment-resistant depression. Conclusion: VEGF holds significant importance in the pathology and treatment of MDD. In-depth exploration of its regulatory mechanisms may provide a basis for the development of novel antidepressant therapies.
Keywords: Vascular endothelial growth factor1, Brain-Derived NeurotrophicFactor2, depression3, blood-brain barrier4, Ketamine5
Received: 11 Jun 2025; Accepted: 14 Aug 2025.
Copyright: © 2025 Wang, Meng, Li and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zeguang Li, Department of Rheumatology and Immunology, First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.